What is HC Wainwright’s Forecast for FHTX FY2026 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Foghorn Therapeutics in a report released on Thursday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($1.14) per share for the year, up from their previous forecast of ($1.16). HC Wainwright currently has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.71) EPS and FY2029 earnings at ($0.17) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last released its quarterly earnings data on Wednesday, March 11th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). The firm had revenue of $9.25 million during the quarter, compared to analyst estimates of $9.50 million.

FHTX has been the topic of a number of other research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Foghorn Therapeutics in a research note on Thursday. Stifel Nicolaus assumed coverage on shares of Foghorn Therapeutics in a research report on Wednesday, December 3rd. They set a “buy” rating and a $12.00 price objective for the company. Wedbush restated an “outperform” rating and set a $10.00 price objective on shares of Foghorn Therapeutics in a report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Foghorn Therapeutics in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered shares of Foghorn Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Foghorn Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $11.13.

Foghorn Therapeutics Stock Performance

NASDAQ FHTX opened at $4.90 on Monday. The business has a 50 day simple moving average of $5.66 and a 200 day simple moving average of $5.05. Foghorn Therapeutics has a 52-week low of $2.94 and a 52-week high of $6.95. The stock has a market cap of $287.63 million, a price-to-earnings ratio of -4.19 and a beta of 3.02.

Hedge Funds Weigh In On Foghorn Therapeutics

A number of large investors have recently bought and sold shares of FHTX. Deutsche Bank AG raised its holdings in shares of Foghorn Therapeutics by 7.3% in the fourth quarter. Deutsche Bank AG now owns 27,421 shares of the company’s stock valued at $148,000 after purchasing an additional 1,861 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Foghorn Therapeutics by 48.0% in the third quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock worth $35,000 after purchasing an additional 2,305 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Foghorn Therapeutics by 16.1% during the second quarter. JPMorgan Chase & Co. now owns 18,723 shares of the company’s stock worth $88,000 after purchasing an additional 2,597 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Foghorn Therapeutics by 18.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,908 shares of the company’s stock valued at $84,000 after purchasing an additional 2,812 shares in the last quarter. Finally, Strs Ohio grew its position in Foghorn Therapeutics by 120.5% in the fourth quarter. Strs Ohio now owns 8,600 shares of the company’s stock valued at $46,000 after purchasing an additional 4,700 shares in the last quarter. Institutional investors and hedge funds own 61.55% of the company’s stock.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.